$4.34
+0.15 (+3.58%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MDXG is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
34 interventional · 1 observational · 1 with posted results
Held by 12 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, Qube Research & Technologies Ltd, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC, +7 more) · FINRA short interest 5.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic WoundsNCT06236750Efficacy Endpoint: Healing of Ulcers at 4 Weeks, 8 Weeks, and 12 WeeksOpen-label · Treatment | Not applicable | Recruiting | Device: EPIFIX | Diabetic Foot Ulcer, Venous Leg Ulcer | 75 | Jan 2027 | ≤ 165 d | 2024-02-01 |
| Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUsNCT06600724Percentage of target ulcers achieving wound closureRandomized · Open-label · Treatment | Not applicable | Recruiting | Other: Standard of Care, EPIEFFECT, EPIXPRESS | Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer | 170 | Aug 2026 | ≤ 12 d | 2024-09-19 |
| Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee OsteoarthritisNCT05796765Change in WOMAC pain subscale score between baseline and Day 180Randomized · Triple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study discontinued early by Sponsor | Biological: Micronized DHACM 40 mg, Micronized DHACM 100 mg · Drug: Saline | Knee Osteoarthritis | 43 | 2023-12-15actual | — | 2024-01-17 |
| Micronized dHACM vs. Saline in the Treatment of Osteoarthritis of the KneeNCT03485157results2023-12-11Primary Efficacy Endpoint: Change From Baseline in Visual Analog Scale (VAS) for Pain at 90 DaysRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Biological: Micronized dHACM · Drug: Saline | Knee Osteoarthritis | 447 | 2022-04-19actual | — | 2023-12-11 |
| Micronized dHACM Injectable for the Treatment of Achille TendonitisNCT03414255Change in VAS scoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Biological: Micronized DHACM · Drug: Saline Injection | Tendonitis;Achilles | 146 | 2021-03-30actual | — | 2022-05-19 |
| Micronized dHACM Injectable for the Treatment of Plantar FasciitisNCT03414268Change in VAS scoreRandomized · Double-masked · Treatment | Phase 3 | Completed | Other: Micronized dHACM · Drug: Saline Injection | Fasciitis, Plantar | 208 | 2021-03-17actual | — | 2022-05-19 |
| A Single Center, Prospective, Case Series of the Treatment of Pressure Ulcers and Decubitus Ulcers.NCT03529578Percentage of subjects with complete wound closure of study ulcerOpen-label · Treatment | Not applicable | Completed | Procedure: dHACM | Pressure Ulcer | 20 | 2019-06-01actual | — | 2020-11-13 |
| Use of Human Dehydrated Amnion Chorion Allograft in Laryngectomy/PharyngectomyNCT03479463observationalIncidence of Pharayngocutaneous Fistula Development (PCF) | — | Terminatedsponsor's stated reason: Slow enrollment | Biological: Dehydrated human amnion/chorion membrane | Larynx Cancer, Pharynx Cancer, Pharyngocutaneous Fistula | 8 | 2019-03-30actual | — | 2020-11-13 |
| Use of Human Dehydrated Amnion/Chorion (DHACM) Allograft in Partial NephrectomyNCT03323021Recovery of Renal FunctionRandomized · Single-masked · Treatment | Not applicable | Completed | Other: Dehydrated human amnion/chorion membrane, Standard of Care | Partial Nephrectomy, Kidney Cancer, Renal Function Aggravated | 61 | 2019-02-21actual | — | 2020-11-13 |
| Dehydrated Human Amnion Chorion Membrane (dHACM) vs. Control in the Treatment of Partial Thickness Burns.NCT02765737Healing RateRandomized · Open-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Slow enrollment, issues with inclusion/exclusion and choice of control | Other: Dehydrated Human Amnion/Chorion Membrane · Device: Mepilex Ag | Treatment of Partial Thickness Burns | 23 | Jan 2019actual | — | 2022-05-17 |
| Use of Human Dehydrated Umbilical Cord Allograft in Supraspinatus Tendon RepairNCT03084068ASES scoreRandomized · Double-masked · Treatment | Not applicable | Completed | Other: Human dehydrated umbilical cord allograft, Placebo | Shoulder Injury, Shoulder Sprain, Supraspinatus Tear | 25 | 2019-01-17actual | — | 2019-12-18 |
| Use of Human Dehydrated Amnion Chorion Allograft in Closed HemorroidectomyNCT03479489Reported Patient PainOpen-label · Treatment | Not applicable | Completed | Other: Human dehydrated amnion chorion allograft | External Hemorrhoid, External Hemorrhoid Thrombosed | 11 | 2018-12-30actual | — | 2019-12-18 |
| Micronized dHACM Injectable for the Treatment of Plantar FasciitisNCT0242719120% improvement over baseline Visual Analog Scale for PainRandomized · Single-masked · Treatment | Phase 2/3 | Completed | Other: AmnioFix® Injectable · Drug: Saline Injection | Fasciitis, Plantar | 147 | Aug 2018actual | — | 2020-11-17 |
| Dehydrated Human Umbilical Cord Allograft in the Management of Diabetic Foot UlcersNCT02844660Complete Ulcer ClosureRandomized · Open-label · Treatment | Not applicable | Completed | Biological: EpiCord · Other: Standard of Care | Diabetic Foot Ulcers | 130 | Jul 2018actual | — | 2022-05-13 |
| Trial of Dehydrated Human Amnion/Chorion Membrane (dHACM) In the Management of Diabetic Foot UlcersNCT01693133Percentage of subjects with complete closure of the study ulcerRandomized · Open-label · Treatment | Not applicable | Completed | Other: Standard of Care: Moist Wound Therapy and Offloading, EpiFix plus Standard of Care | Diabetic Foot Ulcer | 132 | Jun 2018actual | — | 2018-09-24 |
| Amniotic Membrane in Decompressive Craniectomy to Reduce ScarringNCT02033824Degree of scarring between the galea and the dura, as assessed by the Ease of Dissection (EOD) Score and histological analysis upon reoperation in patients receiving craniectomy with durotomy.Randomized · Single-masked · Treatment | Not applicable | Completed | Other: dHACM · Procedure: Craniectomy | Scarring | 7 | Jun 2018actual | — | 2018-08-23 |
| dHACM in Lumbar Decompression and Microdiscectomy SurgeryNCT02300909Oswestry Disability IndexRandomized · Single-masked · Prevention | Not applicable | Completed | Procedure: Lumbar Decompression Surgery, Microdiscectomy Surgery · Other: Dehydrated Human Amnion/Chorion Membrane (dHACM) | Scarring, Spinal Stenosis, Herniated Disc | 143 | Jun 2018actual | — | 2018-08-23 |
| DHACM in Robotic Assisted Laparoscopic Prostatectomy (RALP)NCT02526173Potency as assessed by Sexual Health Inventory for Men (SHIM) ScoreRandomized · Single-masked · Treatment | Not applicable | Completed | Procedure: RALP using full nerve sparing technique · Other: dHACM Application | Erectile Dysfunction | 230 | 2018-06-21actual | — | 2018-09-28 |
| Case Series of Weekly Applications of dHACM in Treatment of Pressure UlcersNCT02861560Healing RateOpen-label · Treatment | Not applicable | Completed | Other: dHACM | Pressure Ulcer | 10 | May 2018actual | — | 2018-08-24 |
| Protocol for the Clinical Evaluation of Lyophilized Amniotic Fluid in the Treatment of Knee OsteoarthritisNCT03074526Reduction in PainRandomized · Double-masked · Treatment | Not applicable | Completed | Other: Amniotic Fluid, Saline Placebo | Osteoarthritis, Knee | 156 | 2018-04-25actual | — | 2020-11-13 |
| Use of dHACM in the Treatment of Venous Leg UlcersNCT02011503Time to 100% epithelialization of study ulcerRandomized · Open-label · Treatment | Not applicable | Completed | Procedure: Multi-layer compression therapy · Other: Application of dHACM | Leg Ulcer | 128 | 2017-08-05actual | — | 2018-08-24 |
| Evaluation of Amniotic Fluid Product in Knee OsteoarthritisNCT02768155Reduction in PainRandomized · Open-label · Treatment | Not applicable | Completed | Other: Amniotic Fluid 4.0ml dose, Amniotic Fluid 2.0ml dose, Placebo Control | Osteoarthritis of the Knee | 60 | Apr 2017actual | — | 2017-10-26 |
| dHACM In the Treatment of Diabetic Foot UlcersNCT02587104The percentage of subjects with complete closure of the study ulcerOpen-label · Treatment | Not applicable | Completed | Other: EpiFix | Diabetic Foot Ulcers | 16 | May 2016actual | — | 2017-08-25 |
| dHACM Mesh In the Treatment of Diabetic Foot UlcersNCT02589210The percentage of subjects with complete closureOpen-label · Treatment | Not applicable | Completed | Other: EpiFix Mesh | Diabetic Foot Ulcers | 10 | Jan 2016actual | — | 2017-08-25 |
| DHACM vs Other Commercially Available TreatmentsNCT01921491Proportion of ulcers achieving 100% epithelialization in the dHACM group vs other commercially available product and control.Randomized · Open-label · Treatment | Not applicable | Completed | Procedure: Dressing Application · Device: Offloading | Diabetic Foot Ulcer | 105 | Sep 2015actual | — | 2020-11-04 |
| Amniotic Membrane in Total Knee Replacements to Reduce ScarringNCT02088567Increased range of motion between both groups as measured by goniometerRandomized · Single-masked · Treatment | Not applicable | Completed | Procedure: Total Knee Arthroplasty · Other: Application of dHACM | Scarring | 52 | Oct 2014actual | — | 2015-09-23 |
| Randomized Clinical Trial Using Amniotic Membrane in Robotic Assisted Laparoscopic ProstatectomyNCT01832168The proportion of patients achieving return to baseline Sexual Health Inventory for Men (SHIM) score in the AmnioFix group versus the Control group.Randomized · Open-label · Treatment | Not applicable | Completed | Procedure: Robotic Assisted Laparoscopic Prostatectomy · Other: Application of Absorbable Hemostat, Application of dehydrated human amniotic membrane | Pudendal Nerve | 34 | Jun 2014actual | — | 2015-03-17 |
| An Evaluation of the Effect of the AmnioFix Amniotic Membrane Allograft in Patients Undergoing Posterior Instrumentation RemovalNCT01357187Tenacity and frequency of soft tissue adhesionRandomized · Open-label · Treatment | Not applicable | Completed | Other: Scheduled removal of posterior instrumentation with AmnioFix, Scheduled removal of posterior instrumentation without AmnioFix | Adhesions of Soft Tissue | 5 | May 2014actual | — | 2015-03-17 |
| Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg UlcersNCT01552447The proportion of wounds achieving 40% closure in patients treated with amniotic membrane vs. standard of careRandomized · Open-label · Treatment | Not applicable | Completed | Other: EpiFix, Compression Therapy | Venous Leg Ulcer | 98 | May 2014actual | — | 2016-03-16 |
| Micronized Dehydrated Human Amniotic Membrane Suspension in the Treatment of Lateral EpicondylitisNCT01921569Proportion of patients achieving improvement in ASES elbow score in the dHACM treatment group vs the control group.Randomized · Double-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: Study closed by sponsor | Behavioral: Standard of Care Therapy · Other: dHACM Injection, Normal Saline Injection | Epicondylitis, Lateral Humeral | 5 | Mar 2014actual | — | 2015-09-24 |
| Dehydrated Human Amnion/Chorion Membrane Micrografts(dHACM) Injectable in the Treatment of Recalcitrant Plantar FasciitisNCT01996111Reduction of inflammation as measured by AOFAS Hindfoot scoresRandomized · Single-masked · Treatment | Not applicable | Terminatedsponsor's stated reason: Change in Regulatory Status | Procedure: Injection of 1.0 cc of 0.9% Saline, Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension, Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension | Plantar Fasciitis | 14 | Mar 2014actual | — | 2014-06-13 |
| Dehydrated Human Amnion/Chorion Membrane (dHACM) for Recovery After Fractionated Ablative CO2 Laser Resurfacing of the FaceNCT01995604The time to healing for both groups will be assessed as defined by appearance and 100% epithelialization.Randomized · Triple-masked · Treatment | Not applicable | Withdrawn | Other: Application of Sterile 0.9% Saline Solution, Application of dHACM | Scarring | 0 | Nov 2013 | — | 2014-06-13 |
| Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot UlcersNCT01657474Mean time to healingRandomized · Open-label · Treatment | Not applicable | Completed | Other: Weekly application of EpiFix plus standard of care, Biweekly application of EpiFix plus standard of care | Diabetic Foot Ulcer | 40 | Oct 2013actual | — | 2013-12-11 |
| Comparative Study of Amniotic Membrane Injectable in the Treatment of Recalcitrant Plantar FasciitisNCT01659827Change from Baseline in American Orthopaedic Foot and Ankle Society (AOFAS) Hind Foot Score at 8 WeeksRandomized · Single-masked · Treatment | Not applicable | Completed | Other: Marcaine, 0.5cc AmnioFix, 1.25cc AmnioFix, Saline | Plantar Fasciitis | 45 | Mar 2013actual | — | 2013-12-11 |
| Comparative Study of Amniotic Membrane Wound Graft In the Management of Diabetic Foot UlcersNCT01552499The proportion of completely healed ulcers in patients treated with amniotic membrane vs. standard of careRandomized · Open-label | Not applicable | Completed | Other: Standard of care, Applications of EpiFix | Diabetic Foot Ulcer | 25 | Aug 2012actual | — | 2015-08-17 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19